Medtronic plc
MDTNYSE · SIC 3845
$83.20
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↓ -4.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$107.2B
Enterprise Value
$125.9B
P/E
22.3
P/S
2.9
P/B
2.2
EV/EBITDA
13.4
PEG
2.3
FCF Yield
5.1%
Dividend Yield
3.4%
Revenue (TTM)
$36.4B
Net Income (TTM)
$4.8B
Free Cash Flow (TTM)
$5.4B
Gross Margin
—
Operating Margin
17.8%
Net Margin
13.2%
ROE
9.7%
ROIC
7.5%
Debt / Equity
0.6
Net Cash
-$18.7B
Return 1Y
-4.0%
Company profile
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies. It operates through four segments: Cardiovascular, Neuroscience, Medical Surgical Portfolio, and Diabetes Operating Unit. The Neuroscience Portfolio segment offers products for spinal surgeons, neurosurgeons, neurologists; neurologists, pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists.
- CEO
- Geoffrey S. Martha
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 95,000
- Website
- medtronic.com
Management & directors
- Walter Matthew R.SVP, Chief HR Officer
- Kiil Harry SkipEVP & President Cardiovascular
- Blomquist Denise L.Chief Accounting Officer
- Marinaro MichaelEVP, Pres MedSurg and Americas
- Martha GeoffreyChairman and CEO
- Wall Brett A.EVP & Pres Neuroscience
- Pieton ThierryEVP & Chief Financial Officer
- Smith Gregory LEVP Global Ops & Supply Chain
- Quinn MichelleEVP, GC and Secretary
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-09-02
MDT Q4 2026 Earnings
Period ends 2026-04-24
MetricActualYoY
Revenue$9.8B↑ +9.9%
Diluted EPS$0.96↑ +18.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $30.1B | $31.7B | $31.2B | $32.4B | $33.5B | $36.4B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $4.5B | $5.8B | $5.5B | $5.1B | $6.0B | $6.5B |
| Net income | $3.6B | $5.0B | $3.8B | $3.7B | $4.7B | $4.8B |
| Diluted EPS | $2.66 | $3.73 | $2.82 | $2.76 | $3.61 | $3.73 |
| Operating cash flow | $6.2B | $7.3B | $6.0B | $6.8B | $7.0B | $7.3B |
| Free cash flow | $4.9B | $6.0B | $4.6B | $5.2B | $5.2B | $5.4B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 14.9% | 18.2% | 17.6% | 15.9% | 17.8% | 17.8% |
| Net margin | 12.0% | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% |
| Line item | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.9B | $8.4B | $8.3B | $8.9B | $8.6B | $9.0B | $9.0B | $9.8B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $1.3B | $1.6B | $1.6B | $1.4B | $1.4B | $1.7B | $1.5B | $1.9B |
| Net income | $1.0B | $1.3B | $1.3B | $1.1B | $1.0B | $1.4B | $1.1B | $1.2B |
| Diluted EPS | $0.80 | $0.99 | $1.01 | $0.81 | $0.81 | $1.07 | $0.89 | $0.96 |
| Operating cash flow | $986.0M | $958.0M | $2.6B | $2.5B | $1.1B | $925.0M | $2.7B | $2.6B |
| Free cash flow | $466.0M | $554.0M | $2.1B | $2.1B | $584.0M | $457.0M | $2.3B | $2.1B |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 16.1% | 19.0% | 19.9% | 16.1% | 16.8% | 18.8% | 16.2% | 19.1% |
| Net margin | 13.2% | 15.1% | 15.6% | 11.8% | 12.1% | 15.3% | 12.7% | 12.7% |
Company news
Jul 20, 2026
- 56m agoThe Robot Maker's Paradoxtrefis.com
- 1h agoReading Between The Lines Of JNJ Stock's Latest Calltrefis.com
- 1h agoWhat's More Important For Intuitive Surgical: Today's Robots Or Tomorrow's Growth?trefis.com
- 2h ago2026 Minnesota ORBIE Awards Recognize Minnesota’s Top Technology and Security Executivesfinance.yahoo.com
- 9h agoMedtronic to announce financial results for its first quarter of fiscal year 2027finance.yahoo.com
Jul 17, 2026
- 2d agoAbbott Just Showed Its Growth Engine Has More Than One Cylindertrefis.com
- 2d agoWhy This Surgical Robot Stock Is Still a Buy During Its Worst Day in 4 Yearsfinance.yahoo.com
- 3d agoJ&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Whyfinance.yahoo.com
- 3d agoCan Abbott Stock Deliver on Its Second-Half Growth Promise?trefis.com
- 3d agoMedtronic completes SPR Therapeutics acquisitionmedtechdive.com
- 3d agoRapidPulse obtains funding for stroke aspiration systemmedicaldevice-network.com
- 3d agoMedtronic (MDT) Completes SPR Therapeutics Deal To Expand Non Opioid Pain Carefinance.yahoo.com
- 3d agoMedtronic and Apollo Hospitals Announce Strategic Partnership to Establish State-of-the-Art Advanced ICU in Hyderabadfinance.yahoo.com
- 3d agoHow Medtronic’s (MDT) Targeted Device Recall and Earnings Beat Have Changed Its Investment Storyfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Walter Matthew R.· SVP, Chief HR Officer | Sale | 3,102 | $83.15 | $257,931.30 | filing |
| 2026-06-08 | KIIL HARRY SKIP· EVP & President Cardiovascular | Sale | 3,961 | $80.44 | $318,622.84 | filing |
| 2026-06-08 | KIIL HARRY SKIP· EVP & President Cardiovascular | Sale | 228 | $80.45 | $18,342.60 | filing |
| 2026-06-05 | Blomquist Denise L.· Chief Accounting Officer | Tax withholding | 237 | $83.32 | $19,746.84 | filing |
| 2026-06-04 | Martha Geoffrey· Chairman and CEO | Tax withholding | 41,936 | $83.32 | $3.5M | filing |
| 2026-06-04 | Marinaro Michael· EVP, Pres MedSurg and Americas | Tax withholding | 7,471 | $83.32 | $622,483.72 | filing |
| 2026-06-04 | KIIL HARRY SKIP· EVP & President Cardiovascular | Tax withholding | 6,817 | $83.32 | $567,992.44 | filing |
| 2026-06-04 | Walter Matthew R.· SVP, Chief HR Officer | Tax withholding | 2,840 | $83.32 | $236,628.80 | filing |
| 2026-05-26 | Walter Matthew R.· SVP, Chief HR Officer | Option exercise | 9,149 | $0.00 | $0.00 | filing |
| 2026-05-26 | Wall Brett A.· EVP & Pres Neuroscience | Option exercise | 26,907 | $0.00 | $0.00 | filing |
| 2026-05-26 | Martha Geoffrey· Chairman and CEO | Option exercise | 94,963 | $0.00 | $0.00 | filing |
| 2026-05-26 | Marinaro Michael· EVP, Pres MedSurg and Americas | Option exercise | 18,994 | $0.00 | $0.00 | filing |
| 2026-05-26 | KIIL HARRY SKIP· EVP & President Cardiovascular | Option exercise | 15,195 | $0.00 | $0.00 | filing |
| 2026-05-26 | Blomquist Denise L.· Chief Accounting Officer | Option exercise | 1,712 | $0.00 | $0.00 | filing |
| 2026-05-01 | Walter Matthew R.· SVP, Chief HR Officer | Tax withholding | 35 | $80.00 | $2,800.00 | filing |
| 2026-04-28 | Blomquist Denise L.· Chief Accounting Officer | Tax withholding | 318 | $81.90 | $26,044.20 | filing |
| 2026-04-28 | Lofton Kevin E | Tax withholding | 207 | $81.90 | $16,953.30 | filing |
| 2026-04-28 | Powell Kendall J | Tax withholding | 207 | $81.90 | $16,953.30 | filing |
| 2026-04-28 | NABEL ELIZABETH G | Tax withholding | 207 | $81.90 | $16,953.30 | filing |
| 2026-04-28 | Lewis Gregory P | Tax withholding | 207 | $81.90 | $16,953.30 | filing |
| 2026-04-28 | HOGAN RANDALL J | Tax withholding | 207 | $81.90 | $16,953.30 | filing |
| 2026-04-28 | Fonseca Lidia | Tax withholding | 207 | $81.90 | $16,953.30 | filing |
| 2026-04-28 | DONNELLY SCOTT C | Tax withholding | 207 | $81.90 | $16,953.30 | filing |
| 2026-04-28 | ARNOLD CRAIG | Tax withholding | 207 | $81.90 | $16,953.30 | filing |
| 2026-04-27 | Blomquist Denise L.· Chief Accounting Officer | Award | 1,508 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.